TNFSF4 and ovarian carcinoma: An mRNA vaccine encoding OX40L (mRNA-2416) for ovarian cancer has entered a phase II trial (NCT03323398), and a triplex mRNA vaccine encoding OX40L/IL23/IL36γ (mRNA-2752) for advanced solid tumors and lymphomas has entered phase I (NCT03739931).